Biogen Company Review & Valuation

BIIB
Nasdaq
Latest Price
281.19USD
Market Capitalization
41.91bUSD

About Biogen Inc.

Biogen Inc.

discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide.

The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.

In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease.

The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis.

Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease.

The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease.

Biogen Inc.

offers products through its sales force and marketing groups.

It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases.

The company was formerly known as Biogen Idec Inc.

and changed its name to Biogen Inc.

in March 2015.

Biogen Inc.

was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
HQ Location
Cambridge, Massachusetts
Wikipedia

Stock Price

Price data not available for Biogen.

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2021 Valuu Analytics Sàrl